Pharmaceutical care as a strategy to improve the safety and effectiveness of patients' pharmacotherapy at a pharmacy school: A practical proposal

Brazilian Journal of Pharmaceutical Sciences

Volumn 50, Issue 1, 2014, Pages 185-193

  Chemello, Clarice ^a   de Souza, Fernanda ^a   Patricio, Eliziane de Souza ^b   Farias, Mareni Rocha ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Community pharmacy; Parkinson's disease treatment; Patients safety; Pharmaceutical care; Pharmacotherapy follow up

Indexed keywords

ANTIPARKINSON AGENT; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA;

AGED; ARTICLE; CASE STUDY; CLINICAL EVALUATION; CLINICAL PHARMACY; CLINICAL PROTOCOL; CONSTIPATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT SAFETY; PHARMACEUTICAL CARE; PHARMACIST ATTITUDE; PROCESS MODEL; PUBLIC HEALTH SERVICE; QUALITY OF LIFE; TREATMENT REFUSAL;

EID: 84900428458     PISSN: 19848250     EISSN: 21759790     Source Type: Journal    
DOI: 10.1590/S1984-82502011000100019     Document Type: Article

References (42)

1. AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS. ASHP guidelines on pharmacist-conducted patient education and counseling. Am. J. Health Syst. Pharm., v.54, p.431-434, 1997.
2. BIALECKA, M.; KURZAWSKI, M.; KLODOWSK-ADUDA, G.; OPALA, G.; TAN, E.K.; DROZDZIK, M. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinsońs disease, levodopa treatment response, and complications. Pharmacogenet. Genomics, v.18, p.815-821, 2008.
3. BRASIL. ANVISA. Resolução da Diretoria Colegiada n° 44, de 17 de agosto de 2009. Dispõe sobre Boas Práticas Farmacêuticas para o controle sanitário do funcionamento, da dispensação e da comercialização de produtos e da prestação de serviços farmacêuticos em farmácias e drogarias e dá outras providências. Available at: http://cfo.org.br/wp-content/uploads/2010/02/180809_rdc_44.pdf. Accessed on: December 2011(a).
4. BRASIL. Ministério da Saúde. Portaria GM/MS no 3.237, de 24 de dezembro de 2007. Aprova as normas de execução e de fnanciamento da assistência farmacêutica na atenção básica em saúde. Available at: http://portal.saude.gov.br/portal/arquivos/pdf/portaria_3237_atencao_basica.pdf. Accessed on: October 2011(b).
5. BRASIL. Ministério da Saúde. Portaria n. 2981, de 26 de novembro de 2009. Aprova o Componente Especializado da Assistência Farmacêutica. Diário Ofcial da União, Poder Executivo, Brasília, DF, 30 de novembro de 2009. Available at: http://portal.saude.gov.br/portal/arquivos/pdf/portaria_gm_2981_3439_ceaf.pdf. Accessed on: October 2011(c).
6. BRASIL. Ministério da Saúde. Portaria no 3.916/MS/GM, de 30 de outubro de 1998. Aprova a Política Nacional de Medicamentos. Diário Ofcial da União, Poder Executivo, Brasília, DF, 10 de novembro de 1998. Available at: http://www.anvisa.gov.br/legis/consolidada/portaria_3916_98.pdf. Accessed on: November 2011(d).
7. CAROD-ARTAL, F.J.; VARGAS, A.P.; Martinez-Martin, P. Determinants of quality of life in Brazilian patients with Parkinson's disease. Mov. Disord., v.22, p.1408-1415, 2007.
8. CHAUDHURI, K.R.; SCHAPIRA, A. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol., v.8, p.464-474, 2009.
9. CHISHOL-MBURNS, M.A.; SPIVEY, C.A.; GARRETT, C.; MCGINTY, H.; MULLOY, L.L. Impact of clinical pharmacy services on renal transplant recipients' adherence and outcomes. Patient. Prefer. Adherence, v.2, p.287-292, 2008.
10. CONSENSUS COMMITTEE. Third consensus of Granada on drug related problems (DRP) and negative outcomes associated with medication (NOM). Ars Pharm., v.48, p.5-17, 2007.
11. GRUPO DE CONSENSO. Documento de consenso en atención farmacéutica. Ministerio de Sanidad y Consumo. Ars Pharm., v.42, p.223-243, 2001.
12. DAVIS, K.L.; EDIN, H.M.; ALLEN, J.K. Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data. Mov. Disord., v.25, p.474-480, 2010.
13. DE CASTRO, M.S.; CORRER, C.J. Pharmaceutical care in community pharmacies: practice and research in Brazil. Ann. Pharmacother., v.41, p.1486-1493, 2007.
14. DE LYRA, D.P.; KHEIR, N.; ABRIATA, J.P.; DA ROCHA, C.E.; DOS SANTOS, C.B.; PELÁ, I.R. Impact of Pharmaceutical Care interventions in the identifcation and resolution of drug-related problems and on quality of life in a group of elderly outpatients in Ribeirão Preto (SP), Brazil. Ther. Clin. Risk Manag., v.3, p.989-998, 2007.
15. GIAF-UGR (Research Group in Pharmaceutical Care). 2005. Dader method to provide pharmacotherapy follow-up. Ars Pharm., v.46, p.309-337, 2005(a).
16. GIAF-UGR (Research Group in Pharmaceutical Care). [Pharmacotherapy Follow-up Guide of patients with Alzheimer]. 2005. Available at: http://www.atencionfarmaceuticaugr.es/index.php?option=com_rem ository&Itemid=62&func=startdown&id=30. Accessed on: January 2012(b).
17. GIAF-UGR (Research Group in Pharmaceutical Care) [Pharmacotherapy Follow-up Guide of patients with schizophrenia] 2009. Available at: http://www.atencionfarmaceuticaugr.es/index.php?option=com_remository&Itemid=62&func=fleinfo&id=107. Accessed on: January 2012.
18. GROSSET, D. European PD Therapy Compliance Study Group. Therapy adherence issues in Parkinson's disease. J. Neurol. Sci., v.289, p.115-118, 2010.
19. GROSSET, K.A.; REID, J.L.; GROSSET, D.G. Medicine taking behavior: implications of suboptimal compliance in Parkinson's disease. Mov. Disord., v.20, p.1397-1404, 2005.
20. HIBBARD, J.H.; STOCKARD, J.; MAHONEY, E.R.; TUSLER, M. Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv. Res., v.39, p.1005-1026, 2004.
21. HOEHN, M.; YAHR, M. Parkinsonism: onset, progression and mortality. Neurology, v.17, p.427-442, 1967.
22. KOSHMAN, S.L.; CHARROIS, T.L.; SIMPSON, S.H.; MCALISTER, F.A.; TSUYUKI, R.T. Pharmacist care of patients with heart failure: a systematic review of randomized trials. Arch. Intern. Med., v.168, p.687-694, 2008.
23. LEE, J.K.; GRACE, K.A.; TAYLOR, A.J. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol A randomized controlled trial. JAMA, v.296, p.2563-2571, 2006.
24. LÉGARÉ, F.; RATTÉ, S.; STACEY, D.; KRYWORUCHKO, J.; GRAVEL, K.; GRAHAM, I.D.; TURCOTTE, S. Interventions for improving the adoption of shared decision making by healthcare professionals. Cochrane Database Syst. Rev., v.12, CD006732, 2010.
25. MARTIN, I.; DAWSON, V.L.; DAWSON, T.M. Recent advances in the genetics of Parkinson's disease. Annu. Rev. Genomics Hum. Genet., v.12, p.301-325, 2011.
26. MCKINSTRY, B.; ASHCROFT, R.E.; CAR, J.; FREEMAN, G.K.; SHEIKH, A. Intervenciones para mejorar la confanza del paciente en el médico y en los grupos de médicos. Cochrane Database Syst. Rev., v.19, CD004134, 2006.
27. MORISKY, D.E.; GREEN, L.W.; LEVINE, D.M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med. Care, v.24, p.67-74, 1986.
28. OBRELI-NETO, P.R.; NOBILI, A.; DE OLIVEIRA BALDONI, A.; GUIDONI, C.M.; DE LYRA JR, D.P.; PILGER, D.; DUZANSKI, J.; TETTAMANTI, M.; CRUCIOL-SOUZA, J.M.; GAETI, W.P.; CUMAN, R.K. Incidence and predictors of potential drug-drug interactions in the elderly: a cross-sectional study in the brazilian primary public health system. J. Pharm. Pharm. Sci., v.15, p.344-354, 2012.
29. PAN AMERICAN HEALTH ORGANIZATION (OPAS). [Brazilian Consensus of Pharmaceutical Care: proposal.] 24 p. Brasília, 2002. Available at: http://www.opas.org.br/medicamentos/docs/PropostaConsensoAtenfar.pdf. Accessed on: November 2011.
30. PAWLOSKI, P.; CUSICK, D.; AMBORN, L. Development of clinical pharmacy productivity metrics. Am. J. Health Syst. Pharm., v.69, p.49-54, 2012.
31. PEREIRA, L.R.L.; FREITAS, O. The evolution of pharmaceutical care and the prospect for Brazil. Rev. Bras. Ciênc. Farm., v.44, p.601-612, 2008.
32. PETO, V.; JENKINSON, C.; FITZPATRICK, R. Determining minimally important differences for the PDQ-39 Parkinson's disease questionnaire. Age Ageing, v.30, p.299-302, 2001.
33. SABATER-HERNÁNDEZ, D.; DE LA SIERRA, A.; BELLVER-MONZÓ, O.; DIVISÓN, J.A.; GOROSTIDI, M.; PERSEGUER-TORREGOSA, Z.; SEGURA, J.; TOUS, S. Action guide for community pharmacists in patients with hypertension and cardiovascular risk. Consensus statement (long version). Ars Pharm., v.52, p.38-58, 2011.
34. SCHRÖDER, S.; MARTUS, P.; ODIN, P.; SCHAEFER, M. Drug-related problems in Parkinsons disease: the role of community pharmacists in primary care. Int. J. Clin. Pharm., v.33, p.674-682, 2011.
35. SHOEMAKER, S.J.; RAMALHO DE OLIVEIRA, D.; ALVES, M.; EKSTRAND, M. The medication experience: preliminary evidence of its value for patient education and counseling on chronic medications. Patient Educ. Couns., v.83, p.443-450, 2011.
36. SOUZA, R.G.; BORGES, V.; CESAR DE AZEVEDO SILVA, S.M.; FERRAZ, H.B. Quality of life Scale in Parkinsons Disease. Arq. Neuropsiquiatr., v.65, p.787-791, 2007.
37. STUART, B.; DAVIDOFF, A.; LOPERT, R.; SHAFFER, T.; SAMANTHA SHOEMAKER, J.; LLOYD, J. Does medication adherence lower Medicare spending among benefciaries with diabetes? Health Serv. Res., v.46, p.1180-1199, 2011.
38. TEDRUS, G.M.A.S.; FONSECA, L.C.; KANGE, P.M. Parkinson' disease: impact of the clinical and cognitive aspects on the quality of life. Dement. Neuropsychol., v.4, p.131-137, 2010.
39. VIKTIL, K.K.; BLIX, H.S. The impact of clinical pharmacists on drug-related problems and clinical outcomes. Basic Clin. Pharmacol. Toxicol., v.102, p.275-280, 2008.
40. WELSH, M. Treatment challenges in Parkinson's disease. Nurse Pract., v.33, p.32-38, 2008.
41. WORLD HEALTH ORGANIZATION. 2003. Adherence to long-term therapies: evidence for action. 211 p. ISBN: 9241545992. Available at: http://whqlibdoc.who.int/ publications/2003/9241545992.pdf. Accessed on: February 2012.
42. WILSON, S.; WAHLER, R.; BROWN, J.; DOLORESCO, F.; MONTE, S.V. Impact of pharmacist intervention on clinical outcomes in the palliative care setting. Am. J. Hosp. Pallit. Care, v.28, p.316-320, 2011.